Evidence map›Paper›PMID 42657058›Full record

ArticleJTO clinical and research reports2026

Response to Trastuzumab Deruxtecan in a Patient With

Malte Verheyen, Lea Ruge, Anne Bunck, Felix John, Lucia Nogova, Richard Riedel, Sofia Stilianakis, Heather Scharpenseel, Matthias Scheffler, Idil Ahmed and 7 more

Abstract readCase Reports
PubMed Full text at PMC Publisher
In one paragraph

Article in JTO clinical and research reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

17 authors.

Malte VerheyenUniversity of Cologne, Faculty of Medicine and University Hospital Cologne, Department I of Internal Medicine, Center for Integrated Oncology Aachen Bonn Cologne Duesseldorf, Lung Cancer Group Cologne (LCGC), Cologne, Germany.
Lea RugeUniversity of Cologne, Faculty of Medicine and University Hospital Cologne, Department I of Internal Medicine, Center for Integrated Oncology Aachen Bonn Cologne Duesseldorf, Lung Cancer Group Cologne (LCGC), Cologne, Germany.
Anne BunckDepartment of Radiology, University of Cologne, Cologne, Germany.
Felix JohnUniversity of Cologne, Faculty of Medicine and University Hospital Cologne, Department I of Internal Medicine, Center for Integrated Oncology Aachen Bonn Cologne Duesseldorf, Lung Cancer Group Cologne (LCGC), Cologne, Germany.
Lucia NogovaUniversity of Cologne, Faculty of Medicine and University Hospital Cologne, Department I of Internal Medicine, Center for Integrated Oncology Aachen Bonn Cologne Duesseldorf, Lung Cancer Group Cologne (LCGC), Cologne, Germany.
Richard RiedelUniversity of Cologne, Faculty of Medicine and University Hospital Cologne, Department I of Internal Medicine, Center for Integrated Oncology Aachen Bonn Cologne Duesseldorf, Lung Cancer Group Cologne (LCGC), Cologne, Germany.
Sofia StilianakisUniversity of Cologne, Faculty of Medicine and University Hospital Cologne, Department I of Internal Medicine, Center for Integrated Oncology Aachen Bonn Cologne Duesseldorf, Lung Cancer Group Cologne (LCGC), Cologne, Germany.
Heather ScharpenseelUniversity of Cologne, Faculty of Medicine and University Hospital Cologne, Department I of Internal Medicine, Center for Integrated Oncology Aachen Bonn Cologne Duesseldorf, Lung Cancer Group Cologne (LCGC), Cologne, Germany.
Matthias SchefflerUniversity of Cologne, Faculty of Medicine and University Hospital Cologne, Department I of Internal Medicine, Center for Integrated Oncology Aachen Bonn Cologne Duesseldorf, Lung Cancer Group Cologne (LCGC), Cologne, Germany.
Idil AhmedUniversity of Cologne, Faculty of Medicine and University Hospital Cologne, Department I of Internal Medicine, Center for Integrated Oncology Aachen Bonn Cologne Duesseldorf, Lung Cancer Group Cologne (LCGC), Cologne, Germany.
Carolin JakobUniversity of Cologne, Faculty of Medicine and University Hospital Cologne, Department I of Internal Medicine, Center for Integrated Oncology Aachen Bonn Cologne Duesseldorf, Lung Cancer Group Cologne (LCGC), Cologne, Germany.
Alexander QuaasInstitute of Pathology, University Hospital Cologne, Cologne, Germany.
Jan Philip WeberMV-Center for Oncology and Hematology, Sachsenring, Cologne, Germany.
Martin SebastianDepartment of Medicine II, Hematology and Oncology, Frankfurt Cancer Institute, University Hospital Frankfurt, Frankfurt, Germany.
Fabian AckerDepartment of Medicine II, Hematology and Oncology, Frankfurt Cancer Institute, University Hospital Frankfurt, Frankfurt, Germany.
Jürgen WolfUniversity of Cologne, Faculty of Medicine and University Hospital Cologne, Department I of Internal Medicine, Center for Integrated Oncology Aachen Bonn Cologne Duesseldorf, Lung Cancer Group Cologne (LCGC), Cologne, Germany.
Sebastian MichelsUniversity of Cologne, Faculty of Medicine and University Hospital Cologne, Department I of Internal Medicine, Center for Integrated Oncology Aachen Bonn Cologne Duesseldorf, Lung Cancer Group Cologne (LCGC), Cologne, Germany.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Small cell transformation (SCT) represents a rare mechanism of acquired resistance to EGFR inhibitors in

Indexed as

Acquired resistanceCase reportEGFR-mutant NSCLCHER2 amplificationSmall cell transformation (SCT)Trastuzumab deruxtecan

Identifiers

PMID42657058
PMCPMC13508615

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.